Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Experimental and Therapeutic Medicine|April 25, 2012
Lymphoma cells with increased anti-oxidant defenses acquire chemoresistanceMargaret E Tome, Jennifer B Frye, Donna L Coyle, et al.
Molecular Cancer Therapeutics|January 14, 2009
UA62784, a novel inhibitor of centromere protein E kinesin-like proteinMeredith C Henderson, Yeng-Jeng Y Shaw, Hong Wang, et al.
Anti-Cancer Drugs|November 1, 2006
Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in miceAlan Pourpak, Ross O Meyers, Betty K Samulitis, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 7, 2009
Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancerArthur Y Shaw, Meredith C Henderson, Gary Flynn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2003
Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individualsH-H Sherry Chow, Yan Cai, Iman A Hakim, et al.
Investigational New Drugs|November 27, 2012
Characterization of a membrane-active anti-tumor agent, UA8967Robert T Dorr, Betty K Samulitis, Lee Wisner, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2009
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancerSteven J Cohen, Mark M Zalupski, Manuel R Modiano, et al.
Nutrition and Cancer|April 30, 2008
Phase 1 study of topical perillyl alcohol cream for chemoprevention of skin cancerSteven P Stratton, Kathy Lynn Saboda, Paul B Myrdal, et al.
Blood|July 13, 2014
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphomaPaul M Barr, Thomas P Miller, Jonathan W Friedberg, et al.
Pageof 4